NCT03915951 2026-03-24
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
Pfizer
Dana-Farber Cancer Institute
University Health Network, Toronto
Allist Pharmaceuticals, Inc.
Abramson Cancer Center at Penn Medicine
H. Lee Moffitt Cancer Center and Research Institute
Swiss Cancer Institute
Pfizer
Novartis